{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:40:32Z","timestamp":1683355232568},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00393-005-0018-z","type":"journal-article","created":{"date-parts":[[2006,1,18]],"date-time":"2006-01-18T08:08:58Z","timestamp":1137571738000},"page":"24-31","source":"Crossref","is-referenced-by-count":4,"title":["Risiko von Infektionen unter einer Behandlung mit Tumornekrosefaktor-\u03b1-Inhibitoren","Risk of infection during treatment with tumor necrosis factor-\u03b1 inhibitors"],"prefix":"10.1007","volume":"65","author":[{"given":"A.","family":"Gaemperli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. F.","family":"Speck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"18_CR1","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1086\/429994","volume":"41","author":"Algood","year":"2005","unstructured":"Algood HM, Lin PL, Flynn JL (2005) Tumor necrosis factor and chemokine interactions in the formation and maintenance of granulomas in tuberculosis. Clin Infect Dis 41 [Suppl 3]:S189\u2013S193","journal-title":"Clin Infect Dis"},{"key":"18_CR2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/107110070402500510","volume":"25","author":"Bibbo","year":"2004","unstructured":"Bibbo C, Goldberg JW (2004) Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 25:331\u2013335","journal-title":"Foot Ankle Int"},{"key":"18_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.autrev.2004.09.001","volume":"4","author":"Botsios","year":"2005","unstructured":"Botsios C (2005) Safety of tumour necrosis factor and interleukin-1 blocking agents in rheumatic diseases. Autoimmun Rev 4:162\u2013170","journal-title":"Autoimmun Rev"},{"key":"18_CR4","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/ard.2004.028209","volume":"63","author":"Calabrese","year":"2004","unstructured":"Calabrese LH, Zein N, Vassilopoulos D (2004) Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 63 [Suppl 2]:1118\u20131124","journal-title":"Ann Rheum Dis"},{"key":"18_CR5","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL et al. (1975) An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 72:3666\u20133670","journal-title":"Proc Natl Acad Sci U S A"},{"key":"18_CR6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/pmj.78.915.47","volume":"78","author":"Chan","year":"2002","unstructured":"Chan AT, Cleeve V, Daymond TJ (2002) Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 78:47\u201348","journal-title":"Postgrad Med J"},{"key":"18_CR7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.8171323","volume":"264","author":"Crowe","year":"1994","unstructured":"Crowe PD, van Arsdale TL, Walter BN et al. (1994) A lymphotoxin-beta-specific receptor. Science 264:707\u2013710","journal-title":"Science"},{"key":"18_CR8","doi-asserted-by":"crossref","unstructured":"Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291\u2013302","DOI":"10.1097\/01.md.0000180044.19285.9a"},{"key":"18_CR9","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1086\/429999","volume":"41","author":"Deepe","year":"2005","unstructured":"Deepe GS Jr (2005) Modulation of infection with histoplasma capsulatum by inhibition of tumor necrosis factor-alpha activity. Clin Infect Dis 41 [Suppl 3]:S204\u2013S207","journal-title":"Clin Infect Dis"},{"key":"18_CR10","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1086\/429992","volume":"41","author":"Deepe","year":"2005","unstructured":"Deepe GS Jr, Smelt S, Louie JS (2005) Tumor necrosis factor inhibition and opportunistic infections. Clin Infect Dis 41 [Suppl 3]:S187\u2013S188","journal-title":"Clin Infect Dis"},{"key":"18_CR11","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1086\/502250","volume":"24","author":"De Rosa","year":"2003","unstructured":"De Rosa FG, Shaz D, Campagna AC et al. (2003) Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect Control Hosp Epidemiol 24:477\u2013482","journal-title":"Infect Control Hosp Epidemiol"},{"key":"18_CR12","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1742-1241.2004.00061.x","volume":"58","author":"Dimakou","year":"2004","unstructured":"Dimakou K, Papaioannides D, Latsi P et al. (2004) Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int J Clin Pract 58:1052\u20131055","journal-title":"Int J Clin Pract"},{"key":"18_CR13","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1086\/429998","volume":"41","author":"Ehlers","year":"2005","unstructured":"Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41 [Suppl 3]:S199\u2013S203","journal-title":"Clin Infect Dis"},{"key":"18_CR14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/j.semarthrit.2003.10.003","volume":"33","author":"Elkayam","year":"2004","unstructured":"Elkayam O, Caspi D, Reitblatt T et al. (2004) The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 33:283\u2013288","journal-title":"Semin Arthritis Rheum"},{"key":"18_CR15","doi-asserted-by":"crossref","first-page":"3013","DOI":"10.1002\/art.11301","volume":"48","author":"Ellerin","year":"2003","unstructured":"Ellerin T, Rubin RH, Weinblatt ME (2003) Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 48:3013\u20133022","journal-title":"Arthritis Rheum"},{"key":"18_CR16","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1086\/430000","volume":"41","author":"Filler","year":"2005","unstructured":"Filler SG, Yeaman MR, Sheppard DC (2005) Tumor necrosis factor inhibition and invasive fungal infections. Clin Infect Dis 41 [Suppl 3]:S208\u2013S212","journal-title":"Clin Infect Dis"},{"key":"18_CR17","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1128\/IAI.69.7.4195-4201.2001","volume":"69","author":"Flynn","year":"2001","unstructured":"Flynn JL, Chan J (2001) Tuberculosis: latency and reactivation. Infect Immun 69:4195\u20134201","journal-title":"Infect Immun"},{"key":"18_CR18","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/ard.61.9.793","volume":"61","author":"Geborek","year":"2002","unstructured":"Geborek P, Crnkic M, Petersson IF, Saxne T (2002) Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 61:793\u2013798","journal-title":"Ann Rheum Dis"},{"key":"18_CR19","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0885066604267854","volume":"19","author":"Giles","year":"2004","unstructured":"Giles JT, Bathon JM (2004) Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 19:320\u2013334","journal-title":"J Intensive Care Med"},{"key":"18_CR20","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR et al. (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"18_CR21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.283.11.1445","volume":"283","author":"Gordin","year":"2000","unstructured":"Gordin F, Chaisson RE, Matts JP et al. (2000) 2000. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA 283:1445\u20131450","journal-title":"JAMA"},{"key":"18_CR22","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1378\/chest.124.6.2395","volume":"124","author":"Hage","year":"2003","unstructured":"Hage CA, Wood KL, Winer-Muram HT et al. (2003) Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 124:2395\u20132397","journal-title":"Chest"},{"key":"18_CR23","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.4049\/jimmunol.163.3.1516","volume":"163","author":"Hayder","year":"1999","unstructured":"Hayder H, Blanden RV, Korner H et al. (1999) Adenovirus-induced liver pathology is mediated through TNF receptors I and II but is independent of TNF or lymphotoxin. J Immunol 163:1516\u20131520","journal-title":"J Immunol"},{"key":"18_CR24","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","volume":"63","author":"Hyrich","year":"2004","unstructured":"Hyrich KL, Silman AJ, Watson KD, Symmons DP (2004) Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann Rheum Dis 63:1538\u20131543","journal-title":"Ann Rheum Dis"},{"key":"18_CR25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2249.1998.00469.x","volume":"111","author":"Kallinowski","year":"1998","unstructured":"Kallinowski B, Haseroth K, Marinos G et al. (1998) Induction of tumour necrosis factor (TNF) receptor type p55 and p75 in patients with chronic hepatitis C virus (HCV) infection. Clin Exp Immunol 111:269\u2013277","journal-title":"Clin Exp Immunol"},{"key":"18_CR26","first-page":"282","volume":"130","author":"Karrer","year":"2000","unstructured":"Karrer W (2000) Tuberculosis in Switzerland \u2014 a millenium problem? Schweiz Med Wochenschr 130:282\u2013290","journal-title":"Schweiz Med Wochenschr"},{"key":"18_CR27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098\u20131104","journal-title":"N Engl J Med"},{"key":"18_CR28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/rheumatology\/keh617","volume":"74","author":"Keystone","year":"2005","unstructured":"Keystone EC (2005) Safety of biologic therapies \u2014 an update. J Rheumatol Suppl 74:8\u201312","journal-title":"J Rheumatol Suppl"},{"key":"18_CR29","doi-asserted-by":"crossref","unstructured":"Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42:617\u2013621","DOI":"10.1093\/rheumatology\/keg263"},{"key":"18_CR30","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","volume":"46","author":"Lee","year":"2002","unstructured":"Lee JH, Slifman NR, Gershon SK et al. (2002) Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 46:2565\u20132570","journal-title":"Arthritis Rheum"},{"key":"18_CR31","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F et al. (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932\u20131939","journal-title":"Lancet"},{"key":"18_CR32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5694\/j.1326-5377.2005.tb06998.x","volume":"183","author":"Nash","year":"2005","unstructured":"Nash PT, Florin TH (2005) Tumour necrosis factor inhibitors. Med J Aust 183:205\u2013208","journal-title":"Med J Aust"},{"key":"18_CR33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","volume":"51","author":"Parke","year":"2004","unstructured":"Parke FA, Reveille JD (2004) Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51:800\u2013804","journal-title":"Arthritis Rheum"},{"key":"18_CR34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/art1.10243","volume":"47","author":"Phillips","year":"2002","unstructured":"Phillips K, Husni ME, Karlson EW, Coblyn JS (2002) Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 47:17\u201321","journal-title":"Arthritis Rheum"},{"key":"18_CR35","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.4049\/jimmunol.168.9.4620","volume":"168","author":"Roach","year":"2002","unstructured":"Roach DR, Bean AG, Demangel C et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168:4620\u20134627","journal-title":"J Immunol"},{"key":"18_CR36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1445-5994.2004.00710.x","volume":"34","author":"Roberts","year":"2004","unstructured":"Roberts L, McColl GJ (2004) Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 34:687\u2013693","journal-title":"Intern Med J"},{"key":"18_CR37","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1084\/jem.186.9.1591","volume":"186","author":"Ruby","year":"1997","unstructured":"Ruby J, Bluethmann H, Peschon JJ (1997) Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors. J Exp Med 186:1591\u20131596","journal-title":"J Exp Med"},{"key":"18_CR38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1286-4579(00)01282-X","volume":"2","author":"Schluter","year":"2000","unstructured":"Schluter D, Deckert M (2000) The divergent role of tumor necrosis factor receptors in infectious diseases. Microbes Infect 2:1285\u20131292","journal-title":"Microbes Infect"},{"key":"18_CR39","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/01.MIB.0000164002.32735.c2","volume":"11","author":"Seddik","year":"2005","unstructured":"Seddik M, Melliez H, Seguy D et al. (2005) Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn\u2019s disease. Inflamm Bowel Dis 11:618\u2013620","journal-title":"Inflamm Bowel Dis"},{"key":"18_CR40","doi-asserted-by":"crossref","first-page":"iv24","DOI":"10.1136\/ard.2005.042531","volume":"64","author":"Stenger","year":"2005","unstructured":"Stenger S (2005) Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 64 [Suppl 4]:iv24\u2013iv28","journal-title":"Ann Rheum Dis"},{"key":"18_CR41","doi-asserted-by":"crossref","unstructured":"Taylor JC, Orkin R, Lanham J (2003) Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology (Oxford) 42:901\u2013902","DOI":"10.1093\/rheumatology\/keg158"},{"key":"18_CR42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.rmed.2004.10.006","volume":"99","author":"Vlachaki","year":"2005","unstructured":"Vlachaki E, Psathakis K, Tsintiris K, Iliopoulos A (2005) Delayed response to anti-tuberculosis treatment in a patient on infliximab. Respir Med 99:648\u2013652","journal-title":"Respir Med"},{"key":"18_CR43","doi-asserted-by":"crossref","first-page":"S194","DOI":"10.1086\/429996","volume":"41","author":"Wallis","year":"2005","unstructured":"Wallis RS, Broder M, Wong J et al. (2005) Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 41 [Suppl 3]:S194\u2013S198","journal-title":"Clin Infect Dis"},{"key":"18_CR44","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev.immunol.23.021704.115719","volume":"23","author":"Ware","year":"2005","unstructured":"Ware CF (2005) Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787\u2013819","journal-title":"Annu Rev Immunol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-005-0018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-005-0018-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-005-0018-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T06:20:36Z","timestamp":1683354036000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-005-0018-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["18"],"URL":"https:\/\/doi.org\/10.1007\/s00393-005-0018-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}